title: Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients: analysis on the maintenance and the change of the original mode of treatment.
abstract: A nation-wide collaborative study to evaluate the long-term effects of bromocriptine in patients with Parkinson's disease was completed as described in the accompanying paper. The present study analysed the same data by paying attention to a group of patients who maintained the original mode of therapy and to a group of patients who changed the mode of treatment by adding levodopa or bromocriptine to the original drug. Surprisingly, 48 among 286 patients in a group of bromocriptine monotherapy maintained the original mode of therapy. This group has particular features of a short duration of illness and a low grade of Hoehn-Yahr's scale. It is noteworthy that this group of patients did not show wearing-off phenomenon. The effects of additional bromocriptine to levodopa for a 5-year period were analysed by comparing two groups of combination therapy and levodopa alone therapy maintained for 5 years, with 106 and 92 patients, respectively. Results were essentially the same as those obtained from the accompanying paper, i.e., in general, treatment by combination with bromocriptine may be more suitable than treatment by levodopa alone. In order to find the best timing of the combination of levodopa and bromocriptine, results of 3 groups were compared, i.e. a group of patients who started with bromocriptine alone and later added with levodopa (82 patients), a group of patients who maintained the combination for 5 years (106 patients) and a group of patients who started with levodopa alone and later added bromocriptine (27 patients). The best results were obtained in the group of 5-year combination.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Mishuku Hospital, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakanishi
authors.forename: I
authors.initials: I
authors.lastname: Kanazawa
authors.forename: M
authors.initials: M
authors.lastname: Iwata
authors.forename: I
authors.initials: I
authors.lastname: Goto
authors.forename: H
authors.initials: H
authors.lastname: Kowa
authors.forename: T
authors.initials: T
authors.lastname: Mannen
authors.forename: Y
authors.initials: Y
authors.lastname: Mizuno
authors.forename: H
authors.initials: H
authors.lastname: Nishitani
authors.forename: N
authors.initials: N
authors.lastname: Ogawa
authors.forename: A
authors.initials: A
authors.lastname: Takahashi
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005684:Gait / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D001971:Bromocriptine; D007980:Levodopa